Evidence map›Paper›PMID 42491265›Full record

Trial reportFrontiers in medicine2026

Feasibility and safety profile of intranasal third-party allogeneic CD45RO

Karima Al-Akioui-Sanz, Fiorela C Dueñas Lopez, Javier Guijarro-Eguinoa, Arturo Gómez Lopez De Las Huertas, Paula Lázaro, Mercedes Gasior, Lidia Pertíñez, Laura Clares Villa, Carmen Mestre Durán, Alberto M Borobia and 3 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06699758 (A Phase I, Single-Center, Open-Label, Dose-Escalation Clinical Trial to Assess the Safety and Tolerability of an Intranasal Memory T Lymphocytes Solution in Adult Females), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06699758 phase1completednot on this map

A Phase I, Single-Center, Open-Label, Dose-Escalation Clinical Trial to Assess the Safety and Tolerability of an Intranasal Memory T Lymphocytes Solution in Adult Females: vRELEASE I. (vRELEASE I)

TypeinterventionalSponsorCristina Calvo ReyRan2025 to 2025Enrolled9ConditionsTo Assess the Safety and Tolerability of Intranasal Administration of a Male Donor Memory T Lymphocyte SolutionArmsCD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors.
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Karima Al-Akioui-Sanz *CIBERER-ISCIII, IdiPAZ-CNIO Translational Research Unit in Pediatric Hemato-Oncology, La Paz University Hospital Research Institute-Spanish National Cancer Center, Madrid, Spain.
Fiorela C Dueñas Lopez *Department of Clinical Pharmacology, La Paz University Hospital (IdiPaz), Madrid, Spain.
Javier Guijarro-EguinoaDepartment of Clinical Pharmacology, La Paz University Hospital (IdiPaz), Madrid, Spain.
Arturo Gómez Lopez De Las HuertasDepartment of Clinical Pharmacology, La Paz University Hospital (IdiPaz), Madrid, Spain.
Paula LázaroBone Marrow and Cell Therapy Unit, Hematology Department La Paz University Hospital, Madrid, Spain.
Mercedes GasiorBone Marrow and Cell Therapy Unit, Hematology Department La Paz University Hospital, Madrid, Spain.
Lidia PertíñezCIBERER-ISCIII, IdiPAZ-CNIO Translational Research Unit in Pediatric Hemato-Oncology, La Paz University Hospital Research Institute-Spanish National Cancer Center, Madrid, Spain.
Laura Clares VillaCIBERER-ISCIII, IdiPAZ-CNIO Translational Research Unit in Pediatric Hemato-Oncology, La Paz University Hospital Research Institute-Spanish National Cancer Center, Madrid, Spain.
Carmen Mestre DuránCIBERER-ISCIII, IdiPAZ-CNIO Translational Research Unit in Pediatric Hemato-Oncology, La Paz University Hospital Research Institute-Spanish National Cancer Center, Madrid, Spain.
Alberto M BorobiaDepartment of Clinical Pharmacology, La Paz University Hospital (IdiPaz), Madrid, Spain.
Antonio BalasHLA Typing, Centro de Transfusiones Comunidad de Madrid, Madrid, Spain.
Cristina CalvoDepartment of Pediatric Infectious Diseases, La Paz University Hospital, Madrid, Spain.
Antonio Pérez-MartínezCIBERER-ISCIII, IdiPAZ-CNIO Translational Research Unit in Pediatric Hemato-Oncology, La Paz University Hospital Research Institute-Spanish National Cancer Center, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Respiratory viral infections remain a major global health challenge, particularly in immunocompromised populations. Although adoptive cell therapies using virus-experienced memory T lymphocytes have demonstrated safety and effectiveness when administered intravenously, the safety profile and feasibility of intranasal delivery of immune effector cells in humans was not previously assessed. Methods: vRELEASE I (NCT06699758) represents a phase I, single-center, open-label, dose-escalation study designed to evaluate the safety profile and feasibility of intranasal administration of off-the-shelf, allogeneic CD45RO Results: Intranasal administration was completed as planned in all nine treated participants. No treatment-emergent adverse events were observed in any cohort during the seven-day safety follow-up period. The highest planned dose, 10 × 10 Conclusion: In this first-in-human, single-center phase I dose-escalation study, intranasal administration of third-party, ready-to-use, allogeneic CD45RO

Indexed as

adoptive T-Cell therapyintranasal administrationmucosal immunityoff-the-shelf cell-based immunotherapyrespiratory viral infectionsthird-party CD45RO+/RA− memory T cells

Identifiers

PMID42491265
PMCPMC13377360

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.